To prove that basic science could be accelerated and more patient-treatment-oriented, in 2004, the Myelin Repair Foundation undertook a five-year myelin repair research program that would lead to new treatments for multiple sclerosis. Our goal was an aggressive one: to license for commercial development the first myelin repair therapeutic target within five years, a process that heretofore was estimated to take 15-20 years. To accomplish this, the MRF harnesses and channels the talents of four of the world’s leading neuroscientists approaching the study of myelin from five different perspectives — immunology, genetics, developmental biology, molecular biology and proteomics — in an outcome-driven research plan.

Accelerating Research Progress

MRF provides the funding, collaborative process strategy, technology and management that enable the scientists to focus their energies on science and not administration. For complex diseases like multiple sclerosis, this unique business/science model significantly accelerates the process of drug discovery.

Since the MRF research team began its research in July of 2004, our rate of progress and the results achieved are unparalleled.  Our accomplishments include the following:

• 19 potential myelin repair targets have been identified.
• 24 new research tools that may have application across all neurological disease research.
• One patent issued and eight more filed by MRF on these discoveries.
• More than 50 articles published in peer-reviewed journals.

Formula for Success

The Myelin Repair Foundation has brought together an aggressive plan with the right scientific team.  The result: We're speeding the time it takes to develop and move scientific discoveries from the laboratory to the MS patient -- making the process up to 100% faster.